Title:
Acalabrutinib (Calquence): Clinical Development, Market Dynamics, and Competitive Landscape
Abstract:
Acalabrutinib, sold under the brand name Calquence, is a second-generation Bruton's tyrosine kinase (BTK) inhibitor developed for the treatment of various types of B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). Acalabrutinib works by blocking the BTK enzyme, a key driver of B-cell survival and proliferation, which plays a significant role in the development of certain types of non-Hodgkin lymphoma. This paper provides an overview of Acalabrutinib's mechanism of action, its development history, approval timeline, global sales performance, market competition, and the current state of generic competition. Additionally, we analyze Acalabrutinib's performance in China and its future potential in the oncology space..jpg)
Keywords:
Acalabrutinib, Calquence, Bruton's tyrosine kinase, chronic lymphocytic leukemia, mantle cell lymphoma, small lymphocytic lymphoma, market competition, generic drugs, BeiGene, sales
Acalabrutinib (Calquence) is a second-generation Bruton's tyrosine kinase (BTK) inhibitor that has emerged as a significant treatment option for various B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). Unlike its predecessor, Ibrutinib (Imbruvica), Acalabrutinib offers a more selective inhibition of BTK, leading to a potentially better safety profile with fewer off-target effects, such as atrial fibrillation and bleeding risks. Calquence has become an essential part of the therapeutic arsenal for CLL and MCL, particularly in patients who have relapsed or are treatment-naïve.
This paper reviews Acalabrutinib's clinical development, its approval timeline, market performance, competitive dynamics, and the growing landscape of generic competition. Furthermore, we assess the drug’s market penetration in China, which has emerged as a key market for oncology drugs.
Acalabrutinib was developed by the pharmaceutical company AstraZeneca, with the goal of creating a more selective BTK inhibitor that would minimize the side effects seen with earlier generation BTK inhibitors like Ibrutinib. The drug was first approved by the U.S. Food and Drug Administration (FDA) in 2017 for the treatment of adults with mantle cell lymphoma (MCL) who had received at least one prior therapy. In the same year, the FDA expanded its approval to include chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Acalabrutinib was subsequently approved in Europe in 2020. The European Medicines Agency (EMA) approved the drug as both monotherapy and in combination with obinutuzumab for the treatment of adults with previously untreated chronic lymphocytic leukemia (CLL). It is also approved for the treatment of adults with CLL who have received at least one prior therapy.
Acalabrutinib works by irreversibly binding to Bruton's tyrosine kinase (BTK), a critical enzyme in the B-cell receptor (BCR) signaling pathway. By inhibiting BTK, Acalabrutinib prevents B-cell activation, survival, and proliferation, which is particularly important in cancers such as CLL, MCL, and SLL, where B-cells are abnormal and proliferate uncontrollably. Acalabrutinib's more selective binding to BTK as compared to Ibrutinib may reduce the occurrence of adverse events, particularly those related to off-target kinases such as C-terminal Src Kinases (CSK), which can lead to atrial fibrillation and bleeding events.
Acalabrutinib’s market performance has been strong since its launch. In 2023, global sales of Calquence (Acalabrutinib) reached $2.5 billion, reflecting a 22% increase year-over-year. The drug’s success is largely driven by its approval for MCL, CLL, and SLL, as well as its broader indication as a first-line therapy in combination with obinutuzumab for CLL.
The drug has found a strong foothold in the U.S. market, where it is used as a second-line therapy for patients who have not responded to initial treatments. However, it also faces significant competition from Ibrutinib (Imbruvica), the first-generation BTK inhibitor, and other emerging therapies.
China represents a rapidly growing market for oncology drugs, with increasing demand for advanced treatments like Acalabrutinib. Calquence was launched in China following its approval by the National Medical Products Administration (NMPA). In the Chinese market, the drug faces competition from both global players and domestic generics.
The approval process in China was expedited, in line with the country’s focus on expanding access to innovative cancer therapies. As the oncology market in China continues to grow, Acalabrutinib’s success is expected to increase, driven by the country's large patient population and increasing healthcare infrastructure. However, the high cost of Calquence remains a barrier for widespread adoption, particularly in lower-income regions.
Acalabrutinib faces competition from a number of other BTK inhibitors, most notably Ibrutinib (Imbruvica), which remains the most well-known and widely used BTK inhibitor. Ibrutinib, while effective, has a broader range of side effects compared to Acalabrutinib, particularly in terms of atrial fibrillation and bleeding risk, which has led to the increasing preference for Acalabrutinib in certain patient populations.
Additionally, acalbrutinib faces competition from zanubrutinib (Brukinsa), a third-generation BTK inhibitor developed by BeiGene, which has shown comparable efficacy in treating MCL and CLL. These newer BTK inhibitors are also expected to provide additional treatment options, reducing the overall market share of Acalabrutinib.
The growth of generic options for Ibrutinib and Acalabrutinib is another challenge. In recent years, multiple generic manufacturers have entered the market, driving down the cost of treatment for patients, especially in emerging markets. However, Acalabrutinib’s more selective mechanism of action may give it a competitive edge over generic versions of Ibrutinib in terms of safety and side effect profile.
While Acalabrutinib has demonstrated superior selectivity and reduced side effects compared to older BTK inhibitors, it is not without its challenges. The drug's high cost remains a key barrier to adoption in both developed and developing markets, including China, where access to new oncology treatments is often limited by cost and reimbursement issues. Additionally, the market is becoming increasingly crowded with newer BTK inhibitors and combination therapies, which could challenge Acalabrutinib’s market share in the long term.
Looking ahead, Acalabrutinib is likely to maintain a strong position in the treatment of B-cell malignancies, particularly if it continues to show superior efficacy and safety profiles in clinical trials. Further exploration of combination therapies, particularly with novel immunotherapies or targeted therapies, could expand its role in treating a broader range of hematologic cancers.
Acalabrutinib (Calquence) has established itself as a vital therapeutic option for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL), offering patients a safer and more targeted alternative to earlier-generation Bruton's tyrosine kinase inhibitors like Ibrutinib. Its growing market presence globally, including in China, highlights its therapeutic potential, despite the increasing competition from both novel BTK inhibitors and generics. Continued innovation and expansion into new indications and combination therapies may allow Acalabrutinib to remain a leader in the competitive oncology market.
Active Pharmaceutical Ingredient
1420477-60-6
Acalabrutinib,Calquence, (chemical grade, purity ≥99.0%) are currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!
Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patents rights are available exclusively for experimental or registration purpose pursuant to national applicable law, and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyer is obligated for evaluation of the patent situation in its domestic market and shall be held liable for uses which do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.
Photo credit: | Pexels (pictures are not products, not actual characters, for display only)
If there is infringement, apologize for deletion, if there is mistake, welcome criticism and correction
In any event, the information or opinions expressed herein are for informational purposes only and do not constitute investment advice to anyone
International Department:
Copyright(C)2018 Anqing Chico Pharmaceutical Co., Ltd.
Supported byChinaChemNet
